Tìm theo
Diflunisal
Các tên gọi khác (8 ) :
  • 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
  • 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid
  • 5-(2,4-Difluorophenyl)salicylic acid
  • Diflunisal
  • Diflunisal
  • Diflunisal
  • Diflunisalum
  • Dolobid
anti inflammatory agents non steroidal
Thuốc Gốc
Small Molecule
CAS: 22494-42-4
ATC: N02BA11
ĐG : A-S Medication Solutions LLC , http://orders.a-smeds.com
CTHH: C13H8F2O3
PTK: 250.1976
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C13H8F2O3
Phân tử khối
250.1976
Monoisotopic mass
250.044150532
InChI
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
InChI Key
InChIKey=HUPFGZXOMWLGNK-UHFFFAOYSA-N
IUPAC Name
5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
Traditional IUPAC Name
diflunisal
SMILES
OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
Độ tan chảy
210-211
Độ hòa tan
Practically insoluble (14.5 mg/L) at neutral or acidic pH.
logP
4.44
logS
-3.5
pKa (strongest acidic)
2.69
pKa (Strongest Basic)
-6.3
PSA
57.53 Å2
Refractivity
60.86 m3·mol-1
Polarizability
22.29 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
3
H Bond Donor Count
2
Physiological Charge
-1
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Diflunisal is a nonsteroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic acid. Chemically, diflunisal differs from aspirin (acetylsalicylic acid) in two respects. The first of these two is the presence of a difluorophenyl substituent at carbon 1. The second difference is the removal of the 0-acetyl group from the carbon 4 position. Diflunisal is not metabolized to salicylic acid, and the fluorine atoms are not displaced from the difluorophenyl ring structure.
Cơ Chế Tác Dụng : Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.
Dược Động Học :
▧ Absorption :
Rapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration.
▧ Protein binding :
At least 98 to 99% of diflunisal in plasma is bound to proteins.
▧ Metabolism :
Hepatic, primarily via glucuronide conjugation (90% of administered dose).
▧ Route of Elimination :
The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces.
▧ Half Life :
8 to 12 hours
Độc Tính : Oral LD50 in rat, mouse, and rabbit is 392 mg/kg, 439 mg/kg, and 603 mg/kg, respectively. Symptoms of overdose include drowsiness, nausea, vomiting, diarrhea, hyperventilation, tachycardia, sweating, tinnitus, disorientation, stupor, and coma. The lowest dose without the presence of other medicines which caused death was 15 grams.

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of diflunisal. Short-term use does not appear to be associated with increased cardiovascular risk (except when used immediately following coronary artery bypass graft (CABG) surgery). Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Severe hepatic reactions, including cholestasis and/or jaundice, have been reported. May cause rash or hypersensitivity syndrome.
Chỉ Định : For symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis.
Tương Tác Thuốc :
  • Acenocoumarol The NSAID, diflunisal, may increase the anticoagulant effect of acenocoumarol.
  • Alendronate Increased risk of gastric toxicity
  • Anisindione The NSAID, diflunisal, may increase the anticoagulant effect of anisindione.
  • Azilsartan medoxomil Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
  • Colesevelam Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
  • Dicoumarol The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol.
  • Eltrombopag Eltrombopag increases levels of Diflunisal via metabolism decrease.
  • Ginkgo biloba Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
  • Indomethacin Concomitant therapy with the two NSAIDs, indomethacin and diflunisal, increases the risk of NSAID-related adverse effects (e.g. GI ulcers, bleeds, increased blood pressure).
  • Lithium The NSAID, diflunisal, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
  • Methotrexate The NSAID, diflunisal, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
  • Pralatrexate NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
  • Probenecid Probenecid increases toxicity of diflunisal
  • Telmisartan Concomitant use of Telmisartan and Diflunisal may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
  • Timolol The NSAID, Diflunisal, may antagonize the antihypertensive effect of Timolol.
  • Trandolapril The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed.
  • Treprostinil The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy.
  • Warfarin The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Liều Lượng & Cách Dùng : Tablet, film coated - Oral - 250 mg
Tablet, film coated - Oral - 500 mg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Everest
    Sản phẩm biệt dược : Anton
  • Công ty : Merck
    Sản phẩm biệt dược : Dolobid
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00861
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=3059
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507807
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C01691
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00130
ChemSpider
http://www.chemspider.com/Chemical-Structure.2951.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/54868-3049-3
PharmGKB
http://www.pharmgkb.org/drug/PA449313
Wikipedia
http://en.wikipedia.org/wiki/Diflunisal
RxList
http://www.rxlist.com/cgi/generic3/diflunisal.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dol1145.shtml
Drugs.com
http://www.drugs.com/cdi/diflunisal.html
... loading
... loading